Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...

In the ongoing battle against triple negative breast cancer, Vanderbilt researchers have uncovered a promising non-invasive ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 targeting immunotherapies.

The inspiration for this article comes from a January 29, 2025, LinkedIn post by robotics entrepreneur Peter Kappes, which reads as follows: “Unitree Robotics is always impressing, as China ...

The excised black, fleshy, ulcerated mass, which was removed ... A histopathologic diagnosis of malignant melanoma was made. Fluorodeoxyglucose-PET (FDG-PET) scans revealed no signs of residual ...

Cytotoxic means toxic to cells. Some people may have chemotherapy as a treatment for advanced melanoma skin cancer. This means the cancer has spread from where it started to another part of the body.

Statistical significance was set at P < .05. Between October 2020 and May 2023, C-CAT registered CGP results from 569 patients with malignant melanoma (Table 1). The majority of samples were tissues ...

Kirsty Stephenson, a nursing simulation fellow based in the clinical skills building at Hull Royal Infirmary, said: “People learn in different ways and seeing what an ulcer actually looks like rather ...